Integrated Report

Overview

The report presents Sumitomo Dainippon Pharma's performance for fiscal 2017 (ended March 31, 2018), highlighting the transition to International Financial Reporting Standards (IFRS) and record consolidated revenue of ¥466.8 billion. Key strategic achievements include expanding overseas business, advancing drug pipelines across Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, and completing the SMaRT commercial manufacturing facility. The company actively promotes work style innovation, employee diversity, and sustainability initiatives aligned with the UN Sustainable Development Goals.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services